Ashley Humphreys
Acute Care · Beaumont, TXNPI 1700313210
Payments from drug & device makers
Across 243 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$562
- Seagen Inc.$535
- GSK$464
- Daiichi Sankyo Inc.$448
- AbbVie$391
- Novartis$315
- plus $5K from 54 others
What the payments were for
- Food & beverage$7,05691%
- Education$6679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$250
- VERQUVO$200
- Flexitouch Plus$139
- Nimbl$139
- OCTARAY MAPPING CATHETER$138
- Repatha$136
- SIR-Spheres Microspheres$133
- LOQTORZI$125
- OJJAARA$125
- Venclexta$117
- EXPAREL$106
- JAKAFI$101
How this compares
$7,723 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $28,351 |
| Anastrozole | 128 | $1,500 |
| Megestrol Acetate | 18 | $1,494 |
| Tamoxifen Citrate | 39 | $981 |
| Gabapentin | 52 | $831 |
| Hydroxyurea | 15 | $621 |
| Letrozole | 19 | $588 |
| Ondansetron OdtOndansetron | 31 | $517 |
| Pantoprazole Sodium | 53 | $355 |
| Promethazine Hcl | 32 | $265 |
| Bicalutamide | 16 | $206 |
| Levothyroxine Sodium | 17 | $132 |
| Prednisone | 31 | $116 |
| Ondansetron Hcl | 12 | $112 |
| Olanzapine | 13 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $257 | $28,35128 claims |
| Lilly USA, LLCOlanzapine | $104 | $10513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in Beaumont
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
- Afton DickersonHouston$27K
- Eleanor WeltgeHouston$25K
- Leslie GutierrezHouston$25K
- Bahia ElkamandSugar Land$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.